Nothing new here, just a repeat of previous presentations point for point. Gary should just voiceover his PowerPoint presentation and email it in. Lots of short term speculation conspicuous in the share price.
IMO 3 options going into next year
SNT partners for 1 indication ( Parkinson's, Scarring or Myleo )
SNT partners with company ABC after some or all phase 2 results, shareholder dilutive as with ARIX previously
SNT receives no direct funding / partnership & has to undertake another dilutive capital raising to move to Phase 3 for some of these drug candidates
Speculative is a good description when you consider funding past June 2025
Add to My Watchlist
What is My Watchlist?
